Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Venner

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Journal of Clinical Epidemiology|July 13, 2004
Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivorsKerry S Courneya, Roanne J Segal, Robert D Reid, et al.
Journal of Virology|July 21, 2022
Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 EnvelopeAnnette N Ratcliff, Colin M Venner, Abayomi S Olabode, et al.
Journal of Clinical Medicine|June 28, 2023
Cardiac Inflammation in Adult-Onset Genetic Dilated CardiomyopathyMaurits A Sikking, Sophie L V M Stroeks, Michiel T H M Henkens, et al.
The Prostate|July 27, 1999
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study GroupD G McLeod, P F Schellhammer, N J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock, D Osoba, M R Stockler, et al.
The Journal of Urology|May 19, 2009
Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy databaseAdrian S Fairey, Niels-Erik B Jacobsen, Michael P Chetner, et al.
Urology|July 22, 1998
Comparison of goserelin and leuprolide in combined androgen blockade therapyM F Sarosdy, P F Schellhammer, R Sharifi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Resistance exercise in men receiving androgen deprivation therapy for prostate cancerRoanne J Segal, Robert D Reid, Kerry S Courneya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03W U Shipley, K A Winter, D S Kaufman, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Journal of Clinical Epidemiology|July 13, 2004
Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivorsKerry S Courneya, Roanne J Segal, Robert D Reid, et al.
Journal of Virology|July 21, 2022
Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 EnvelopeAnnette N Ratcliff, Colin M Venner, Abayomi S Olabode, et al.
Journal of Clinical Medicine|June 28, 2023
Cardiac Inflammation in Adult-Onset Genetic Dilated CardiomyopathyMaurits A Sikking, Sophie L V M Stroeks, Michiel T H M Henkens, et al.
The Prostate|July 27, 1999
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study GroupD G McLeod, P F Schellhammer, N J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock, D Osoba, M R Stockler, et al.
The Journal of Urology|May 19, 2009
Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy databaseAdrian S Fairey, Niels-Erik B Jacobsen, Michael P Chetner, et al.
Urology|July 22, 1998
Comparison of goserelin and leuprolide in combined androgen blockade therapyM F Sarosdy, P F Schellhammer, R Sharifi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Resistance exercise in men receiving androgen deprivation therapy for prostate cancerRoanne J Segal, Robert D Reid, Kerry S Courneya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03W U Shipley, K A Winter, D S Kaufman, et al.
Pageof 10